A Review on Recent Advances and Newer Antidiabetic Drugs in The Management of Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus represents the majority of global diabetes cases and continues to rise as a major public health concern. It is characterized by defective insulin activity, gradual failure of pancreatic β-cells, and altered glucose metabolism. Sedentary lifestyle, diet, genetics, and environmental factors contribute significantly to disease progression. Initially, diabetes management was limited to diet regulation and a few oral agents. However, with increasing complications such as cardiovascular disorders, neuropathy, nephropathy, and retinopathy, there arose an urgent need for safer and more effective medications. Advances in molecular science and biotechnology have ushered in a new era of targeted therapies. These modern drugs not only control blood glucose levels but also support weight management, protect vital organs, and reduce long-term diabetes-related risks. This review highlights both the newer antidiabetic drugs and recent innovations shaping today’s diabetes care. Type 2 diabetes mellitus (T2DM) is an expanding global health problem, closely linked to the epidemic of obesity. Individuals with T2DM are at high risk for both microvascular complications (including retinopathy, nephropathy and neuropathy) and microvascular complications (such as cardiovascular comorbidities), owing to hyperglycaemia and individual components of the insulin resistance (metabolic) syndrome. Environmental factors (for example, obesity, an unhealthy diet and physical inactivity) and genetic factors contribute to the multiple pathophysiological disturbances that are responsible for impaired glucose homeostasis in T2DM. Insulin resistance and impaired insulin secretion remain the core defects in T2DM, but at least six other pathophysiological abnormalities contribute to the dysregulation of glucose metabolism. The multiple pathogenetic disturbances present in T2DM dictate that multiple antidiabetic agents, used in combination, will be required to maintain normoglycaemia me. The treatment must not only be effective and safe but also improve the quality of life. Several novel medications are in development, but the greatest need is for agents that enhance insulin sensitivity, halt the progressive pancreatic β-cell failure that is characteristic of T2DM and prevent or reverse the microvascular complications.

OBJECTIVES 

• To describe the underlying mechanisms contributing to Type 2 Diabetes Mellitus.
• To review traditional and recently introduced antidiabetic medications.
• To discuss the mechanism of action of modern drug classes.
• To provide an updated overview of the latest advancements in diabetes therapy.
• To outline new delivery systems and emerging treatment approaches.
• To compare the benefits and limitations of the latest medications.

EPIDEMIOLOGY

Type 2 diabetes mellitus (T2DM) has emerged as a significant global public health issue. According to the International Diabetes Federation, approximately 382 million adults aged 20–70 years were affected by T2DM worldwide in 2013, with nearly 80% residing in low- and middle-income countries. This figure is projected to increase to 592 million by 2035. The disease burden is particularly high in countries such as China and India, where the prevalence of T2DM has risen sharply despite comparatively lower rates of obesity. At an equivalent body mass index (BMI), Asian populations generally exhibit a higher proportion of body fat, increased abdominal adiposity, and reduced muscle mass, which may contribute to their greater susceptibility to T2DM. Furthermore, under nutrition during fetal development and early life, followed by excessive nutrition in adulthood, accelerates the progression of T2DM, especially in populations experiencing rapid nutritional and lifestyle transitions characterized by altered dietary patterns and reduced physical activity. Overall, the prevalence of T2DM is slightly higher in men than in women .Epidemiological research has enhanced understanding of the behavioural, lifestyle, and biological risk factors associated with T2DM. Increased adiposity, as indicated by elevated BMI, remains the most significant risk factor. Certain dietary patterns are associated with a lower risk of T2DM, independent of body weight, including higher consumption of whole grains, green leafy vegetables, nuts, and coffee, along with reduced intake of refined grains, red and processed meats, and sugar-sweetened beverages. Moderate alcohol consumption has also been linked to a reduced risk. Physical inactivity is a major behavioural contributor, whereas both aerobic exercise and resistance training have protective effects. Prolonged sedentary activities, such as excessive television viewing, are associated with an increased risk of T2DM. Additionally, both short and long sleep durations, rotating shift work, and cigarette smoking are recognized as independent risk factors. Although genetic factors play an important role in individual susceptibility to T2DM, the current global rise in prevalence is largely driven by increasing obesity rates rather than recent genetic changes. However, genetic makeup influences individual responses to environmental and lifestyle factors, contributing to disease development.

PATHOPHYSIOLOGY OF TYPE 2 DIABETES  

1. Insulin Resistance

Insulin resistance is the earliest and most prominent abnormality in T2DM. It refers to the reduced responsiveness of target tissues—mainly skeletal muscle, adipose tissue, and liver—to circulating insulin.

Skeletal muscle: Reduced glucose uptake due to impaired translocation of GLUT-4 transporters.

Adipose tissue: Decreased inhibition of lipolysis results in increased free fatty acid (FFA) release

Liver: Failure of insulin to suppress gluconeogenesis leads to increased hepatic glucose output. Obesity, particularly visceral adiposity, plays a central role in insulin resistance by releasing inflammatory mediators and adipokines that interfere with insulin signaling pathways.

 2. Pancreatic β-Cell Dysfunction

As insulin resistance progresses, pancreatic β-cells initially compensate by increasing insulin secretion. Over time, this compensatory mechanism fails due to:

β-cell exhaustion, Oxidative stress, Glucotoxicity (chronic hyperglycemia), Lipotoxicity (elevated free fatty acids)

This leads to inadequate insulin secretion, especially in response to meals, resulting in persistent postprandial and fasting hyperglycemia.

3. Increased Hepatic Glucose Production

In healthy individuals, insulin suppresses glucose production by the liver during the fed state. In T2DM:  Insulin fails to inhibit hepatic gluconeogenesis, Glycogenolysis continues even after meals. This inappropriate glucose release significantly contributes to elevated fasting blood glucose levels

4. Impaired Incretin Effect

Incretin hormones, mainly glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), enhance insulin secretion after food intake.

In T2DM:  Secretion of GLP-1 is reduced ,Responsiveness to GIP is diminished

This results in decreased glucose-dependent insulin release and contributes to postprandial hyperglycemia

5. Increased Glucagon Secretion

Normally, insulin suppresses glucagon release from pancreatic α-cells.

 In T2DM: α-cells become resistant to insulin ,Excess glucagon is secreted

Elevated glucagon stimulates hepatic glucose production, further worsening hyperglycemia.

6. Altered Renal Glucose Handling

The kidneys play a vital role in glucose homeostasis by reabsorbing filtered glucose through sodium-glucose cotransporter-2 (SGLT2).

In T2DM: Expression and activity of SGLT2 are increased, Excess glucose is reabsorbed instead of being excreted

This contributes to sustained hyperglycemia and forms the basis for SGLT2 inhibitor therapy.

7. Adipose Tissue Dysfunction

Adipose tissue in T2DM becomes metabolically active and releases harmful substances: Pro-inflammatory cytokines (TNF-α, IL-6) , Reduced adiponectin levels

These factors promote insulin resistance, inflammation, and endothelial dysfunction.

8. Chronic Inflammation

Low-grade systemic inflammation is a key feature of T2DM. Inflammatory mediators interfere with insulin signaling and promote β-cell damage, further worsening glucose control.

9. Central Nervous System Dysregulation

The brain regulates appetite and glucose metabolism. 

In T2DM: Impaired insulin signaling in the hypothalamus, Increased appetite and reduced satiety This leads to weight gain and further insulin resistance.

10. The “Ominous Octet” Concept

The combined defects in T2DM are collectively described as the Ominous Octet, which includes:

• Reduced insulin secretion (β-cells)
• Increased glucagon secretion (α-cells)
• Insulin resistance in muscle
• Increased hepatic glucose production
• Increased lipolysis
• Reduced incretin effect
• Increased renal glucose reabsorption
• Neurotransmitter dysfunction

BRIEF OVERVIEW OF OLDER THERAPIES 

1) Metformin 

Metformin is a biguanide and is considered the first-line oral antidiabetic drug for the management of Type 2 Diabetes Mellitus. It lowers blood glucose levels primarily by reducing hepatic glucose production and improving insulin sensitivity without stimulating insulin secretion. Therefore, it carries a minimal risk of hypoglycemia.

MOA of Metformin

• Inhibition of Hepatic Gluconeogenesis

The principal action of metformin occurs in the liver.

Metformin suppresses the synthesis of glucose by inhibiting gluconeogenic pathways.

It reduces the conversion of lactate, glycerol, and amino acids into glucose.

This leads to a significant reduction in fasting blood glucose levels.

This effect is largely mediated through activation of AMP-activated protein kinase (AMPK).

• Activation of AMP-Activated Protein Kinase (AMPK)

Metformin increases intracellular AMP levels by inhibiting mitochondrial respiratory chain complex I. Elevated AMP activates AMPK, a key cellular energy regulator. Activated AMPK suppresses genes involved in gluconeogenesis and lipogenesis while enhancing fatty acid oxidation. As a result, glucose production by the liver is decreased and insulin sensitivity is improved.

2) Sulfonylureas

Sulfonylureas are oral hypoglycemic agents used in the treatment of Type 2 Diabetes Mellitus, and they act primarily by stimulating insulin secretion from pancreatic β-cells.

MOA of sulfonylureas

These drugs bind to the sulfonylurea receptor-1 (SUR-1), which is a regulatory subunit of the ATP-sensitive potassium (K?ATP) channels present on the β-cell membrane. Binding of sulfonylureas leads to closure of these potassium channels, resulting in reduced potassium efflux and depolarization of the β-cell membrane. Membrane depolarization subsequently opens voltage-gated calcium channels, allowing an influx of calcium ions into the β-cells. The rise in intracellular calcium concentration triggers exocytosis of insulin-containing granules, thereby increasing insulin release into the bloodstream. The released insulin enhances glucose uptake by peripheral tissues and suppresses hepatic glucose production, leading to a reduction in blood glucose levels. Sulfonylureas require functioning pancreatic β-cells to exert their effect and are therefore effective only in Type 2 Diabetes Mellitus. Since they stimulate insulin secretion irrespective of blood glucose levels, they carry a risk of hypoglycemia and may also cause weight gain. Overall, sulfonylureas lower blood glucose by increasing endogenous insulin secretion through closure of ATP-sensitive potassium channels in pancreatic β-cells.

3) Thiazolidinediones

Thiazolidinediones are oral antidiabetic agents used in the treatment of Type 2 Diabetes Mellitus and act mainly by improving insulin sensitivity in peripheral tissues.

MOA of Thiozolidinediones 

 Drugs of this class, such as pioglitazone and rosiglitazone, exert their effect by binding to and activating peroxisome proliferator-activated receptor gamma (PPAR-γ), a nuclear receptor predominantly expressed in adipose tissue and also present in skeletal muscle and liver. Activation of PPAR-γ alters the transcription of genes involved in glucose and lipid metabolism, leading to enhanced insulin responsiveness of target tissues. Through PPAR-γ activation, thiazolidinediones increase the expression and translocation of GLUT-4 transporters, which promotes greater glucose uptake by skeletal muscle and adipose tissue. They also reduce insulin resistance by decreasing the release of free fatty acids and proinflammatory cytokines from adipose tissue, while increasing levels of adiponectin, an insulin sensitizing adipokine. Additionally, these drugs help redistribute fat from visceral to subcutaneous depots, further improving metabolic control. Thiazolidinediones lower blood glucose levels without directly stimulating pancreatic β-cells, resulting in a low risk of hypoglycemia when used alone, although they may be associated with weight gain and fluid retention.

4) α-Glucosidase Inhibitors  

Alpha-glucosidase inhibitors are oral antidiabetic drugs used in the management of Type 2 Diabetes Mellitus and primarily act by delaying the digestion and absorption of carbohydrates in the intestine. 

MOA of Alpha-glucosidase inhibitors 

These drugs, such as acarbose, miglitol, and voglibose, competitively inhibit the α-glucosidase enzymes located in the brush border of the small intestine. Α-Glucosidase enzymes are responsible for breaking down complex carbohydrates and disaccharides into absorbable monosaccharides like glucose. By inhibiting these enzymes, alpha-glucosidase inhibitors slow the conversion of dietary carbohydrates into glucose, resulting in a delayed and reduced postprandial rise in blood glucose levels. This mechanism does not involve stimulation of insulin secretion and therefore does not increase the risk of hypoglycemia when the drugs are used alone. The undigested carbohydrates pass into the colon, where they are fermented by intestinal bacteria, which may lead to gastrointestinal side effects such as flatulence and diarrhea. Overall, alpha-glucosidase inhibitors help control postprandial hyperglycemia by reducing the rate of intestinal glucose absorption .Conventional drugs continue to play an important role, but newer agents provide additional metabolic and organ-protective advantages.

NEWER ANTIDIABETIC DRUGS & RECENT ADVANCES  

1) Dipeptidyl peptidase-4 (DPP-4) Inhibitors. :- Examples: Sitagliptin, Linagliptin,

Saxagliptin

Mechanism of action:-

They block the DPP-4 enzyme, increasing incretin hormones that boost insulin release and suppress glucagon. Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral antidiabetic drugs used in the management of Type 2 Diabetes Mellitus. This class of drugs includes Sitagliptin, Vildagliptin , Saxagliptin , linagliptin, and Alogliptin. They exert their glucose-lowering effect by enhancing the action of incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are released from the intestine in response to food intake. Under normal conditions, incretin hormones are rapidly degraded by the enzyme DPP-4. DPP-4 inhibitors block this enzyme, thereby preventing the breakdown of GLP-1 and GIP and prolonging their activity in the circulation. Increased levels of active incretins stimulate glucose dependent insulin secretion from pancreatic β-cells and suppress glucagon release from α-cells. This leads to reduced hepatic glucose production and improved glycemic control, particularly after meals. Since insulin secretion stimulated by DPP-4 inhibitors is glucose-dependent, the risk of hypoglycemia is minimal when these drugs are used alone. Additionally, DPP-4 inhibitors are weight-neutral and well tolerated, making them suitable for long-term use in patients with Type 2 Diabetes Mellitus

Fig:- MOA of DPP 4 Inhibitors

2) Sodium–glucose co-transporter-2(SGLT2) Inhibitors:- Examples: Dapagliflozin, Empagliflozin, Canagliflozin

Mechanism: They prevent glucose reabsorption in kidneys, promoting glucose elimination through urine. These drugs act at the level of the kidneys by inhibiting the SGLT2 protein located in the proximal convoluted tubules. Under normal physiological conditions, SGLT2 is responsible for reabsorbing nearly 90% of filtered glucose back into the bloodstream. By blocking SGLT2, these drugs prevent renal glucose reabsorption and promote urinary glucose excretion (glucosuria). This leads to a reduction in plasma glucose levels independent of insulin secretion or insulin action. As a result, both fasting and postprandial blood glucose levels are lowered.

Fig:- MOA of SGLT-2 inhibitors

Clinicalbenefits:

1. Help reduce body weight
2. Lower blood pressure
3. Provide significant cardiovascular and renal protection

3) GLP-1 Receptor Agonists:- Examples: Liraglutide, Dulaglutide, Semaglutide

MOA of GLP-1 RA

GLP-1 Receptor Agonists (RAs) mimic the natural incretin hormone GLP-1, activating its receptor (GLP-1R) to stimulate glucose-dependent insulin release, inhibit glucagon secretion, slow gastric emptying, and signal satiety in the brain, all leading to better blood sugar control and weight loss, primarily by activating the G-protein/cAMP pathway in various tissues like the pancreas and CNS. 

Fig:- MOA of GLP – 1 receptor antagonist

Advantages:

Promote substantial weight loss

Cardioprotective

Minimal hypoglycemia risk

4) Dual Incretin Agonists (GLP-1 + GIP):- Example: Tirzepatide

Why it’s important:

Dual agonists activate both GLP-1 and GIP receptors, offering stronger glucose reduction and weight loss effects than traditional agents.

Benefits:

1. Greater HbA1c improvement
2. Significant reduction in obesity
3. Strong potential to replace multiple older drugs

5) Next-Generation Insulin Analogs

Ultra-fast acting:  Fiasp , Lyumjev ,Ultra-long acting  :- Deglude , Glargine U300

Advantages:

1. Mimic natural insulin release
2. More stable glucose control
3. Lower episodes of hypoglycemia

Modern Combination Therapies

Popular combinations:

1. Metformin + SGLT2 inhibitor
2. Metformin + DPP-4 inhibitor
3. GLP-1 agonist + basal insulin

Why used:

Better glucose control

Simpler dosing

Improved patient adherence

TECHNOLOGICAL ADVANCES IN DIABETES CARE 

• Continuous Glucose Monitoring (CGM)  - Provides real-time glucose readings to guide therapy adjustments
• Insulin Pumps - Deliver precise amounts of insulin continuously and during meals.
• Smart Insulin Pens - Record insulin doses and connect with monitoring apps.
• Artificial Pancreas - A closed-loop system that automatically delivers insulin based on glucose levels.
• Inhaled Insulin - A painless alternative to prandial insulin injections.

EMERGING FUTURE THERAPIES 

• Stem Cell Transplantation - Aims to regenerate insulin-producing β-cells.
• Gene Editing Approaches - CRISPR-based strategies to modify defective metabolic pathways.
• Oral Insulin Development - Several formulations are under investigation.
• Oral GLP-1 Analogues - Oral semaglutide already approved and growing in use.
• Immunotherapy - Focused on delaying β-cell destruction in high-risk individuals.

COMPARATIVE OVERVIEW OF MODERN DRUGS 

Table 1 – Comparative overview of modern drugs